Anakinra

Recombinant human IL-1 receptor antagonist

Not yet authorised in Switzerland.

Indications: Rheumatoid arthritis in combination with methotrexate, cryopyrin-associated periodic syndromes (CAPS) [Muckle Wells syndrome (MWS), Familial cold autoinflammatory syndrome (FCAS), Familial cold urticaria (FCU), Neonatal-onset multisystem inflammatory disorder (NOMID)/ Chronic infantile neurodermoarticular syndrome (CINCA)], Still’s syndrome, systemic juvenile idiopathic arthritis.

No

Not yet authorised in Switzerland.

Pre-filled syringe.

Differential blood count, transaminases, alkaline phosphatase, creatinine, urinalysis, screening for HBV, HCV, HIV and TB (optional: including chest X-ray).

Differential blood count, transaminases, alkaline phosphatase, gamma-GT, creatinine, urea, urinalysis and urine sediment.

Every 2–4 weeks for the first 6 months, then every 3 months.

Depending on the indication.

In adults: 100 mg daily. In children: 1–2 mg/kg body weight daily.

Dose reduction in cases of severe/end-stage renal failure (e.g. administration every 2 days).

Clinical response after approximately 2 weeks, maximum clinical response within 12 weeks.

Do not use in combination with TNF-α inhibitors (increased risk of infection with no clinical benefit); renal impairment.

14,657 (at a dose of 100 mg per day).

Pause for 1–2 days before surgery.

Insufficient data.

3–6 per cent (in some cases, transient seropositivity without any loss of efficacy or increased incidence of ADRs).

Hypersensitivity to the active substance or to any of the other ingredients. Neutropenia (absolute neutrophil count [ANC] < 1.5 × 10⁹/L). Insufficient data are available regarding pregnancy and breastfeeding; therefore, use is not recommended.

Headache, serious infections, neutropenia, thrombocytopenia, allergic reactions, elevated transaminases, non-infectious hepatitis, hypercholesterolaemia, injection-site reaction.

No live vaccines. Do not use in combination with TNF-α inhibitors (increased risk of serious infectious diseases). Monitor the concentration of CYP450 substrates with a narrow therapeutic index when administered concomitantly.

Start TB prophylaxis at least 1 month before the start of treatment.